Summary Physiological significance of vasoactive intestinal polypeptide (VIP), a putative co-transmitter of the cholinergic neuron innervating sweat glands, was investigated by its local effect on drug-induced sweating. VIP, methacholine chloride (MCH), or VIP plus MCH dissolved in 0.1 ml of 0.9% NaCI solution to a specified concentration was injected intradermally at the center of a forearm test area of 15 cm2 and the sweat rate was recorded continuously by capacitance hygrometry. In a cool environment (Ta, 23°C), VIP failed to cause sweat secretion, but increased the rate of MCH-induced sweating, most markedly at a concentration of 10-5 g/ml, where the rise in local skin temperature was the greatest. On an area anesthetized by nerve block in a hot environment (Ta, 35°C), the effect was less obvious and less consistent, indicating that the sweatfacilitatory effect of VIP is reduced under the condition of passive cutaneous vasodilation. It may be postulated that VIP plays a role in securing ample oxygen supply to functioning sweat glands, especially with a relatively high cutaneous vasoconstrictor tone.
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Y. YAMASHITA et al. vasodilation, respectively. Furthermore, in the submandibular salivary gland of the cat, marked potentiation of salivary secretion was observed as ACh and VIP were administered together, and close cooperation of both substances was suggested LUNDBERG and HOKFELT, 1983) . VIP was assumed to be more important for vasodilation and ACh for secretion. The present study was proposed to investigate the role of VIP in human sweatgland activity through examination of its local effect on sweating, induced by methacholine chloride (MCH).
Subjects were four healthy male volunteers, aged 21-26, wearing only short pants. In Series 1, experiments were carried out on the subject sitting on a stool in a climatic chamber controlled at an air temperature of 23°C (Ta) and a relative humidity of 40%. Cylindrical acrylate capsules, each covering a 15-cm2 area of the volar aspect of the forearm, were ventilated with dry air at a flow rate of 1.5 1/mmn and the humidity change of the efferent air was sensed by a high-sensitive capacitance hygrometer (Vaisala HMI 14) and recorded continuously on a penwriting oscillograph. Local sweat rates on six areas (three areas each bilaterally) were recorded in single experiments. The temperature of the test area was monitored continuously by a thermistor thermometer, encased in the capsule. After confirming that sweating was absent, sweat capsules were temporarily taken off and a solution was injected intradermally at the center of the test area, and sweat capsules were replaced. The thermistor was located on the skin surface adjacent to the wheal produced by the injection. The injected solutions were VIP (Protein Research Foundation), MCH (Mecholyl chloride, Merck & Co.) and a combination of the two, dissolved in 0.1 ml of 0.9°0 NaCI solution to a specified concentration and the solvent alone was used as the control. The solutions were warmed proximately to the skin temperature. Concentrations of the drugs were 10-', 10-6 g/ml for MCH (0.01, 0.l ,ig/0.1 ml), and 10-', 10-6, 10-s, 5 x 10-5 g/ml for VIP (0.01, 0.1, 1, 5 µg/0.1 ml). Immediately following the injection of any solution, a transient increase in evaporation rate was noted in a greater or lesser degree on the humidity recording. Such episode was considered to be due to mixing of the ambient vapor, evaporation of 70°c alcohol solution (used for disinfection of the injection site), and leakage of the injected agent and or oozing of blood. In the case of 0.9°c NaCI solution, the evaporation rate returned to the baseline level within 2 min after the replacement of the capsule. Therefore, data for the initial 2 min were discarded. In Series 2, drug-induced sweating was observed on an anesthetized area with nerve block in the presence of generalized thermal sweating at Ta of 35°C and a relative humidity of 40%. Sweat rate and skin temperature were recorded similarly to Series 1. Bilateral forearm areas where spontaneous sweating was present at the same rate were selected as test areas. The medial and lateral antebrachial cutaneous nerves were blocked at a level slightly distal to the elbow by perineural injections of 2% Xylocaine (Fujisawa Pharm. Co.) with 1: 200,000 adrenaline to stop sweating on the test areas. Drug-induced sweating was observed thereon, similarly to Series 1. Concentrations of the drugs were 10-6 g/ml for MCH, and 10-', 10-6, and 10-5 g/ml for VIP.
In an additional experiment, the change and the distribution of skin temperature following injections of VIP at various concentrations were observed with thermistor thermometers and infrared thermograph (Fujitsu Infra-eye 150) in a cool environment. Figure 1 shows records of forearm skin temperature and local sweat rate following injections of MCH alone, MCH with VIP, and VIP alone in a cool environment. MCH injection induced sweating, the rate of which maintained the peak level for about 10 min. The rate of sweating induced by MCH combined with VIP was greater than that by MCH alone: Facilitation of the MCH-induced sweating was most remarkable with VIP at a concentration of l0 -5 g/ml, where the sweat rate reached a peak level in about 10 min, decreased thereafter relatively rapidly, and returned to the baseline level in 35 min. A distinct increase in the local skin temperature was also noted, although it only became distinct as the sweat rate declined. On the other hand, the rise in skin temperature was obscure in the case of MCH combined with 10-6 g/ml VIP and not recognizable with 10-' g/ml VIP. A notable increase of skin temperature was observed by the injection of 10-5 g/ml VIP alone, which induced no sweating. Less increases in the local skin temperature with no sweating were noted with VIP alone at concentrations of 10-8, 10-', 10-6, and 5 x 10-5 g/ml, the maximum rise in skin temperature being 0.1, 0.3, 0.9, and 1.3°C, respectively, as compared with 1.9°C at 10-5 g/ml VIP. Thus the vasodilative effect of VIP appeared to be parallel with its facilitatory effect on MCH-induced sweating. Less and delayed rises in skin temperature with various combinations of VIP and MCH can be attributed to skin cooling by evaporation of sweat. The sweat-facilitatory effect of VIP was evaluated by comparison of the peak rates of sweating induced by the injection of MCH combined with VIP to those by MCH alone. The calculated ratio for each subject is shown in Fig. 2 . In general, combinations of VIP of 10-6 and 10-5 g/ml gave much higher values than those of 10-' or 5 x 10-5 g/ml; VIP of 10-5 g/ml was higher than 10-6 g/ml in most of the cases. Accordingly, VIP was considered to induce facilitation of sweating most effectively at a concentration of 10 5 g/ml. Since the amount of sweat discharge in response to 10-7g/ml MCH was so small, MCH at a concentration of 10-6 g/ml was preferred for use in Series 2, so as to minimize technical errors.
In Series 2, the local skin temperature increased slightly as sweating stopped following the cutaneous nerve block. However, it decreased again soon after the drug induced sweat discharge, and then increased gradually. The peak rates of sweating induced by the injection of MCH with VIP are compared to those by MCH alone under the regional nerve block in Fig. 3 . For comparison, the corresponding results from Series 1 are also illustrated. The sweat-facilitatory effect of VIP was less in Series 2 than in Series 1 in most of the cases. In Subject 3, sweating was even reduced with VIP. In Series 2 also, the ratio was generally greater at VIP concentrations of 10_6 and 10 -5 g/ml than at 10 -' g/ml. Figure 4 illustrates thermographic changes in skin temperature following the intradermal injections of VIP at concentrations of 10-8, 10-', 10-6, and 10-5 g/ml. The skin temperature of the test area rose in good correspondence with the concentration of VIP injected, and endorses the results obtained with thermistor thermometers in Series 1.
Exposure to heat induces cutaneous vasodilation due to reduced activity in vasoconstrictor nerves, and the blood flow increases further as sweating emerges (RODDIE et al., 1957) . This "active" component of vasodilation is considered to be associated with sweat-gland activity, for the vascular change follows only the onset of sweating (LovE and SHANKS, 1962) . It has been proposed that the active cutaneous vasodilation accompanied by sweat gland activity is due to the release of kallikrein which catalyzes bradykinin locally (Fox and HILTON, 1958) . However, this hypothesis has been disputed (SCHACHTER, 1969; FREwIN et al., 1973; ROWELL, 1981) . On the other hand, it has been demonstrated that stimulation of the nerve, innervating the salivary gland of the cat, releases both ACh and VIP at the neuroglandular junction and causes salivary secretion and local vasodilation, the latter being unaffected by atropinization. The intimate cooperation of these two agents has been suggested by the marked potentiation of both the secretory and circulatory responses observed when both substances are administered together . In the present study, VIP per se failed to cause sweat secretion, whereas MCH-induced sweating was augmented when combined with VIP. These results coincide with the potentiation of ACh effect on the salivary gland of the cat with VIP . The sweat rates returned to the baseline in about 30 min in spite of different peak levels in all cases. This may have been caused by the accelerated washout of the injected MCH due to the vasodilative action of VIP, or attributed to the time required for the dissolution of MCH. From the observations that the degree of the rise in skin temperature with various concentrations of VIP coincides fairly well with the degree of the enhancement of MCH-induced sweating, the sweat-facilitatory effect of VIP may. be attributed to its vasodilative function. The sweat-facilitatory effect of VIP in Series 2 was less than that in Series 1, although the flush was observed around the site of VIP injection. This fact indicates that the facilitation of sweating is less marked under vasoconstrictor nerve block than under the vasoconstrictive condition in a cool environment. As thermal sweating is induced in a hot environment where cutaneous vasculature has been dilated, the vasodilative effect of VIP may be of less significance. However, it is speculated that the increase in blood flow due to the vasodilative effect of VIP has more meaning for oxygen supply than for hydration, for the sweat gland activity acquires energy from an aerobic glycolysis which requires a relatively large quantity of oxygen. It may be postulated that VIP plays a role in securing ample oxygen supply to functioning sweat glands, especially in a condition where cutaneous vasoconstrictor tone predominates. It should be noted, however, that numerous VIP-positive nerve terminals have been located close to secretory acini and reabsorptive ducts of eccrine sweat glands (HEINZ-ERIAN et al., 1985; VAALASTI et al., 1985) . Therefore, other effects of VIP on sweat-gland function ought to be taken into consideration also. VIP may enhance the affinity of the muscarinic receptors for acetylcholine, as indicated by LUNDBERG et al. (1982) . HEINZ-ERIAN et al.'(1985) noted a highly deficient innervation by VIP-containing nerves in patients with cystic fibrosis and suggested that VIP may influence the secretion and composition of sweat by promoting C1 secretion by acini and/or its reabsorption by ducts, as had been demonstrated in other tissues (KREJS et a!.,1980; NATHANSON et al., 1983) . However, the present observations that the sweatfacilitatory effect of VIP was obscure and inconsistent in the presence of passive vasodilation suggest that the effect is largely secondary to vasodilation.
